Vor Biopharma

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2023, and provided a business update.

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%

Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells.

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, reported its financial results for the three-month period and full year that ended December 31, 2022, and provided a business update. The post Vor Bio Announces Q4 And FY 2022 Results appeared first on Pulse 2.0.

Vor Bio Announces Q4 And FY 2022 Results

CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2022, and provided a business update.

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, presented clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (previously VOR33) in patients with acute myeloid leukemia (AML). In the first patient, trem-cel maintained hematopoiesis through three cycles of Mylotarg (gemtuzumab ozogamicin), which was well-tolerated at the initial dose level of 0.5 mg/m2. A second patient has successfully received a trem-cel transplant and engrafted normally. These data were presented today by Miguel-Angel Perales, MD, Chief, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center in a late-breaking poster at the 2023 Tandem Meetings (Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®) in Orlando, FL.

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) in patients with acute myeloid leukemia (AML) has been accepted as a late-breaking poster presentation at the 2023 Tandem Meetings, the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place February 15-19 in Orlando, Florida.

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities' 3rd Annual Oncology Conference.

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million.

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced initial clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukemia (AML). The data observed from the first treated patient support the potential of a trem-cel transplant to be successfully manufactured, to engraft normally, and to maintain blood counts following treatment with the CD33-targeted therapy Mylotarg. The clinical trial continues to enroll patients and additional data are expected in 2023.

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2022 and provided a business update.

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO). Dr. Attar brings more than 20 years of demonstrated clinical experience to the position, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies.

Vor Bio Appoints Eyal C. Attar, M.D.

-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

Facility to support clinical manufacturing for Vor Bio's novel cell and genome engineering pipeline while reducing the time and cost required to manufacture its eHSC and CAR-T product candidates Facility to support clinical manufacturing for Vor Bio's novel cell and genome engineering pipeline while reducing the time and cost required to manufacture its eHSC and CAR-T product candidates

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

The consensus price target hints at a 298.3% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 295% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 295%

CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2022, and provided a business update.

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2022, and provided a business update.

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating virtually in two upcoming investor conferences:

Vor to Participate in Two Upcoming Investor Conferences

Presentations showcase breadth of Vor Bio's multiplex editing capability including base editing of human hematopoietic stem and progenitor cells (HSPCs) enabling new therapeutic approaches following transplant in patients with acute myeloid leukemia (AML) Presentations showcase breadth of Vor Bio's multiplex editing capability including base editing of human hematopoietic stem and progenitor cells (HSPCs) enabling new therapeutic approaches following transplant in patients with acute myeloid leukemia (AML)

Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer for Vor Bio plans to retire. The Vor Bio clinical team is fully resourced and continues to actively recruit patients into VBP101, the Company's Phase 1/2a first-in-human study of VOR33 in patients with AML who are at high risk of relapse. An executive search to replace Dr. Slapak is underway.

Vor Bio Announces Retirement of Chief Medical Officer

BOCA RATON, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #Biomanufacturing--Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases.

Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2021, and provided a business update.

Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in three upcoming investor conferences:

News for Vor Biopharma Stock (VOR)